Biosimilars approved in Europe Posted 08/07/2011
Last update: 7 July 2017 In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved centrally via the European Medicines Agency (EMA) and not nationally.
EMA first developed guidelines for the approval of biosimilars via an abbreviated registration process during 2005 to 2006, and since then EMA has developed many general and specific guidelines for biosimilars [1]. Omnitrope (somatropin) was the first product approved in the EU as a biosimilar in 2006 [2]. To date, EMA has approved 38 biosimilars within the product classes of human growth hormone, granulocyte colony-stimulating factor, erythropoesis stimulating agent, insulin, follicle-stimulating hormone (FSH), parathyroid hormone and tumour necrosis factor (TNF)-inhibitor, for use in the EU, see Table 1. Three biosimilar approvals have been withdrawn; two for filgrastim biosimilars: Filgrastim ratiopharm in April 2011 and Biograstim in December 2016, and one for a somatropin biosimilar (Valtropin) in May 2012. This leaves a total of 35 biosimilars approved for use in Europe. Table 1: EMA approved biosimilars* Product name Active substance Therapeutic area Authorization date Manufacturer/Company name Abasaglar (previously Abasria)
insulin Diabetes 9 Sep 2014
Eli Lilly/Boehringer Abseamed epoetin alfa
Anaemia 28 Aug 2007 Medice Arzneimittel Pütter Accofil filgrastim Neutropenia 18 Sep 2014 Accord Healthcare Amgevita adalimumab
Crohn’s disease 22 Mar 2017 Amgen Benepali etanercept
Axial spondyloarthritis 14 Jan 2016 Samsung Bioepis Bemfola follitropin alfa Anovulation (IVF) 24 March 2014 Finox Biotech Binocrit epoetin alfa
Anaemia 28 Aug 2007 Sandoz Biograstim filgrastim
Cancer
15 Sep 2008 CT Arzneimittel Blitzima rituximab
Non-Hodgkin lymphoma CHMP positive opinion on 18 May 2017 Celltrion Epoetin alfa Hexal epoetin alfa
Anaemia 28 Aug 2007 Hexal Erelzi etanercept
Ankylosing spondylitis 27 Jun 2017 Sandoz Filgrastim Hexal filgrastim
Cancer 6 Feb 2009 Hexal Filgrastim ratiopharm filgrastim
Cancer
15 Sep 2008 Ratiopharm Flixabi infliximab
Ankylosing spondylitis 26 May 2016 Samsung Bioepis Grastofil filgrastim Neutropenia 18 Oct 2013 Apotex Imraldi adalimumab
Ankylosing spondylitis CHMP positive opinion 23 Jun 2017 Samsung Bioepis Inflectra infliximab
Ankylosing spondylitis 10 Sep 2013 Hospira Inhixa enoxaparin sodium Venous thromboembolism 15 Sep 2016 Techdow Europe Insulin lispro Sanofi Insulin lispro Diabetes mellitus CHMP positive opinion on 18 May 2017 Sanofi-Aventis Lusduna insulin glargine Diabetes 4 Jan 2017 Merck (MSD) Movymia teriparatide Osteoporosis 11 Jan 2017 Stada Arzneimittel Nivestim filgrastim
Cancer 8 Jun 2010 Hospira Omnitrope somatropin
Pituitary dwarfism 12 Apr 2006 Sandoz Ovaleap follitropin alfa Anovulation (IVF) 27 Sep 2013 Teva Pharma Ratiograstim filgrastim
Cancer 15 Sep 2008 Ratiopharm Remsima infliximab
Ankylosing spondylitis 10 Sep 2013 Celltrion Retacrit epoetin zeta
Anaemia 18 Dec 2007 Hospira Ritemvia rituximab
Wegener granulomatosis CHMP positive opinion on 18 May 2017 Celltrion Rixathon rituximab
Chronic B-cell lymphocytic leukaemia 19 Jun 2017 Sandoz Riximyo rituximab
Chronic B-cell lymphocytic leukaemia CHMP positive opinion on 21 April 2017 Sandoz Silapo epoetin zeta
Anaemia 18 Dec 2007 Stada Arzneimittel Solymbic adalimumab
Ankylosing spondylitis 22 Mar 2017 Amgen Terrosa teriparatide Osteoporosis 4 Jan 2017 Gedeon Richter Tevagrastim filgrastim
Cancer 15 Sep 2008 Teva Generics Thorinane enoxaparin sodium Venous thromboembolism 15 Sep 2016 Pharmathen Truxima rituximab
Chronic lymphocytic leukaemia 17 Feb 2017 Celltrion Tuxella rituximab
Wegener granulomatosis CHMP positive opinion on 18 May 2017 Celltrion Valtropin somatropin
Pituitary dwarfism
24 Apr 2006 BioPartners Zarzio filgrastim
Cancer 6 Feb 2009 Sandoz *Data collected on 12 May 2011, updated on 7 July 2017
CHMP: Committee for Medicinal Products for Human Use; VF:in vitrofertilization. The positive opinion reached by the EMA’s Committee for Medicinal Products for Human Use (CHMP) on 27 June 2013 for the infliximab biosimilars Inflectra and Remsima was a landmark decision, proving that the biosimilar concept can be successfully applied to such complex molecules as monoclonal antibodies. The positive opinion reached by the EMA’s Committee for Medicinal Products for Human Use (CHMP) on 26 July 2014 for the insulin glargine biosimilar came as a relief to diabetes sufferers in Europe, after the disappointing withdrawal of the applications for three biosimilar insulin products by Marvel LifeSciences in November 2012 [3].
Related articles EMA approves first monoclonal antibody biosimilar Biosimilar monoclonal antibody approved in Korea
References Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.
glargine
Ingelheim
Cancer
Chronic kidney failure
Psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Spondylarthritis
Suppurativa hidradenitis
Ulcerative colitis
Uveitis
Psoriatic arthritis
Plaque psoriasis
Rheumatoid arthritis
Chronic kidney failure
Haematopoietic stem cell transplantation
Neutropenia
Withdrawn on 22 Dec 2016
Chronic B-cell lymphocytic leukaemia
Cancer
Chronic kidney failure
Juvenile rheumatoid arthritis
Psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Haematopoietic stem cell transplantation
Neutropenia
Haematopoietic stem cell transplantation
Neutropenia
Withdrawn on 20 Apr 2011
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Arthritis
Crohn’s Disease
Hidradenitis suppurativa
Psoriatic arthritis,
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Uveitis
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Haematopoietic stem cell transplantation
Neutropenia
Prader-Willi syndrome
Turner syndrome
Haematopoietic stem cell transplantation
Neutropenia
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Autologous blood transfusion
Cancer
Chronic kidney failure
Microscopic polyangiitis
Non-Hodgkin Lymphoma
Microscopic polyangiitis
Non-Hodgkin Lymphoma
Rheumatoid arthritis
Wegener granulomatosis
Microscopic polyangiitis
Non-Hodgkin Lymphoma
Rheumatoid arthritis
Wegener granulomatosis
Autologous blood transfusion
Cancer
Chronic kidney failure
Crohn’s disease
Psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Hidradenitis suppurativa
Ulcerative colitis
Haematopoietic stem cell transplantation
Neutropenia
Granulomatosis with polyangiitis
Microscopic polyangiitis
Non-Hodgkin’s lymphoma
Rheumatoid arthritis
Microscopic polyangiitis
Non-Hodgkin Lymphoma
Chronic B-cell lymphocytic leukaemia
Turner syndrome
Withdrawn on 10 May 2012
Haematopoietic stem cell transplantation
Neutropenia
Source: EMA
Remsima approved in Colombia
1. GaBI Online - Generics and Biosimilars Initiative. EU guidelines for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jul 4]. Available from: www.gabionline.net/Guidelines/EU-guidelines-for-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars use in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jul 4]. Available from: www.gabionline.net/Reports/Biosimilars-use-in-Europe
3. GaBI Online - Generics and Biosimilars Initiative. Marvel withdraws biosimilar insulin applications [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jul 4]. Available from: www.gabionline.net/Biosimilars/News/Marvel-withdraws-biosimilar-insulin-applications
Source: EMA